-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Frexalimab in Relapsing Multiple Sclerosis (RMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Frexalimab in Relapsing Multiple Sclerosis (RMS) Drug Details: Frexalimab (INX-021) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Siponimod Fumarate in Relapsing Multiple Sclerosis (RMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Siponimod Fumarate in Relapsing Multiple Sclerosis (RMS) Drug Details:Siponimod fumarate (Mayzent / Wan Li Neng /...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6035 in Relapsing Multiple Sclerosis (RMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RG-6035 in Relapsing Multiple Sclerosis (RMS)Drug Details:RG-6035 is under development for the treatment of relapsing multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Atorvastatin + Fluconazole + Minocycline) in Relapsing Multiple Sclerosis (RMS) Drug Details: A fixed-dose combination...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Hidradenitis Suppurativa Drug Details: LOU-064 is under development for the treatment of chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Relapsing Remitting Multiple Sclerosis (RRMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details: LOU-064 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Chronic Urticaria Or Hives
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Chronic Urticaria Or Hives Drug Details: LOU-064 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Atopic Dermatitis (Atopic Eczema) Drug Details: LOU-064 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cetuximab Sarotalocan in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Sarotalocan in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: Cetuximab sarotalocan (Akalux)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cetuximab Sarotalocan in Cutaneous Squamous Cell Carcinoma (cSCC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Sarotalocan in Cutaneous Squamous Cell Carcinoma (cSCC) Drug Details: Cetuximab sarotalocan (Akalux) is a...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.